TEM - Tempus AI, Inc. So'nggi Yangiliklar | Finranks

26.03.2026

Tempus AI Reinforces Market Position With Collaborations in 2026

TEM expands 2026 reach via strategic collaborations, boosting oncology, diagnostics and AI-driven insights to enhance care and drug development.

26.03.2026

Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?

Tempus (TEM) reported earnings 30 days ago. What's next for the stock?

23.03.2026

Tempus AI's Diagnostics and Data Arms Drive Long-Term Growth Story

Tempus AI's dual-engine model drives $1.27B revenues, with Diagnostics dominating and Data monetization accelerating growth and pricing leverage.

21.03.2026

Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.

Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor can build from scratch.

17.03.2026

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer. Part of.

16.03.2026

Tempus AI Advances Clinical Applications and Healthcare Software

TEM expands its clinical software push with TIME trial-matching, Tempus Next care intelligence and an upgraded Tempus One AI assistant for providers.

12.03.2026

Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics

TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.

Videolar

08.08.2025

Positive

TEM Earnings Rally: A.I. Use in Health Care, Drug Discovery

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
TEM	BTIG Research	Buy	undefined >> $60	April 21st 2025
TEM	JP Morgan	Neutral	$50 >> $55	February 25th 2025
TEM	William Blair	Market Perform	undefined >> undefined	February 12th 2025

Press-relizlar

17.03.2026

Tempus AI, Inc. (TEM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tempus AI, Inc. (TEM)

Tempus AI Reinforces Market Position With Collaborations in 2026

Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?

Tempus AI's Diagnostics and Data Arms Drive Long-Term Growth Story

Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

Tempus AI Advances Clinical Applications and Healthcare Software

Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics

Videolar

Reytinglar oshishi / pasayishi

Press-relizlar

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference